Martine Rothblatt

United Therapeutics Corporation To Present At The 2021 Wedbush PacGrow Healthcare Virtual Conference

Retrieved on: 
Tuesday, August 3, 2021
Businesspeople, LGBT people, LGBT, United Therapeutics, Martine Rothblatt

and RESEARCH TRIANGLE PARK, N.C., Aug. 3, 2021 /PRNewswire/ --United Therapeutics Corporation (Nasdaq: UTHR) announced today that Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer of United Therapeutics, will provide an overview and update on the company's business during a fireside chat session at the 2021 Wedbush PacGrow Healthcare Virtual Conference.

Key Points: 
  • and RESEARCH TRIANGLE PARK, N.C., Aug. 3, 2021 /PRNewswire/ --United Therapeutics Corporation (Nasdaq: UTHR) announced today that Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer of United Therapeutics, will provide an overview and update on the company's business during a fireside chat session at the 2021 Wedbush PacGrow Healthcare Virtual Conference.
  • The session will take place virtually on Wednesday, August 11, 2021, from 8:35 a.m. to 9:05 a.m., Eastern Daylight Time, and can be accessed via a live webcast on the United Therapeutics website at https://ir.unither.com/events-and-presentations .
  • United Therapeutics Corporation focuses on the strength of a balanced, value-creating biotechnology model.
  • Lung Biotechnology is the first public benefit corporation subsidiary of a public biotechnology or pharmaceutical company.

United Therapeutics Corporation To Present At The 39th Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Monday, January 4, 2021
Businesspeople, LGBT people, LGBT, United Therapeutics, Martine Rothblatt

and RESEARCH TRIANGLE PARK, N.C., Jan. 4,2021 /PRNewswire/ --United Therapeutics Corporation (Nasdaq: UTHR) announced today that Dr. Martine Rothblatt, Chairman and Chief Executive Officer of United Therapeutics, will provide an overview and update on the company's business during a presentation and question and answer session at the 39th annual J.P. Morgan Healthcare Conference.

Key Points: 
  • and RESEARCH TRIANGLE PARK, N.C., Jan. 4,2021 /PRNewswire/ --United Therapeutics Corporation (Nasdaq: UTHR) announced today that Dr. Martine Rothblatt, Chairman and Chief Executive Officer of United Therapeutics, will provide an overview and update on the company's business during a presentation and question and answer session at the 39th annual J.P. Morgan Healthcare Conference.
  • The presentation will take place virtually on Monday, January 11, 2021, from 10:50 a.m. to 11:30 a.m., Eastern Standard Time, and can be accessed via a live webcast on the United Therapeutics website at https://ir.unither.com/events-and-presentations .
  • United Therapeutics Corporation focuses on the strength of a balanced, value-creating biotechnology model.
  • Lung Biotechnology is the first public benefit corporation subsidiary of a public biotechnology or pharmaceutical company.

United Therapeutics Releases Its First Corporate Responsibility Report

Retrieved on: 
Tuesday, November 24, 2020
Accounting, Economy, Business, Sustainability metrics and indices, Sustainability Accounting Standards Board, Sustainable business, Corporate social responsibility, Global Reporting Initiative, Sustainability accounting, Ethical investment, Martine Rothblatt, United Therapeutics

"Environmental sensitivity and corporate responsibility have been part of our DNA since our inception," said Martine Rothblatt, Ph.D., Chairman and Chief Executive Officer of United Therapeutics.

Key Points: 
  • "Environmental sensitivity and corporate responsibility have been part of our DNA since our inception," said Martine Rothblatt, Ph.D., Chairman and Chief Executive Officer of United Therapeutics.
  • "In light of growing interest in ESG from investors and other stakeholders, we are pleased to share our corporate responsibility achievements in this inaugural report."
  • United Therapeutics developed its initial Corporate Responsibility Report with guidance from members of its Board of Directors and the frameworks provided by both the Global Reporting Initiative (GRI) and Sustainability Accounting Standards Board (SASB).
  • United Therapeutics plans to continue to report on its corporate responsibility efforts on an annual basis and plans to issue its next report around mid-year 2021.

United Therapeutics Corporation To Present At The 38th Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Monday, January 6, 2020
Businesspeople, LGBT people, Lawyers, United Therapeutics, Martine Rothblatt, Biotechnology, NASDAQ Biotechnology Index

and RESEARCH TRIANGLE PARK, N.C., Jan. 6, 2020 /PRNewswire/ --United Therapeutics Corporation (Nasdaq: UTHR) announced today that Martine Rothblatt, Ph.D., Chairman and Chief Executive Officer of United Therapeutics, will provide an overview and update on the company's business at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, California.

Key Points: 
  • and RESEARCH TRIANGLE PARK, N.C., Jan. 6, 2020 /PRNewswire/ --United Therapeutics Corporation (Nasdaq: UTHR) announced today that Martine Rothblatt, Ph.D., Chairman and Chief Executive Officer of United Therapeutics, will provide an overview and update on the company's business at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, California.
  • United Therapeutics Corporation focuses on the strength of a balanced, value-creating biotechnology model.
  • Lung Biotechnology is the first public benefit corporation subsidiary of a public biotechnology or pharmaceutical company.
  • Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.

United Therapeutics And DEKA Announce FDA Clearance Of The Unity Subcutaneous Delivery System For Remodulin®

Retrieved on: 
Tuesday, May 7, 2019
United Therapeutics, Businesspeople, LGBT people, Lawyers, Martine Rothblatt, Pulmonary hypertension, Infusion pump, Treprostinil, Deka, PAH

The RemUnity system, which has been jointly developed by United Therapeutics and DEKA, is indicated for subcutaneous delivery of Remodulin to treat pulmonary arterial hypertension, or PAH.

Key Points: 
  • The RemUnity system, which has been jointly developed by United Therapeutics and DEKA, is indicated for subcutaneous delivery of Remodulin to treat pulmonary arterial hypertension, or PAH.
  • United Therapeutics intends to launch the product when this additional FDA clearance has been obtained.
  • United Therapeutics and DEKA are also developing a version of the system that includes disposable cartridges that are pre-filled as part of the manufacturing process.
  • "We developed the RemUnity system to address safety and patient convenience problems with current subcutaneous infusion pumps," said Martine Rothblatt, Chairman and Chief Executive Officer of United Therapeutics.

United Therapeutics Corporation To Present At 37th Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Monday, December 31, 2018
Business, United Therapeutics, LGBT, Gender, Martine Rothblatt, Biotechnology

and RESEARCH TRIANGLE PARK, N.C., Dec. 31, 2018 /PRNewswire/ --United Therapeutics Corporation (NASDAQ: UTHR) announced today that Martine Rothblatt, Ph.D., Chairman and Chief Executive Officer of United Therapeutics, will provide an overview and update on the company's business at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, California.

Key Points: 
  • and RESEARCH TRIANGLE PARK, N.C., Dec. 31, 2018 /PRNewswire/ --United Therapeutics Corporation (NASDAQ: UTHR) announced today that Martine Rothblatt, Ph.D., Chairman and Chief Executive Officer of United Therapeutics, will provide an overview and update on the company's business at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, California.
  • [uthr-g]
    United Therapeutics Corporation focuses on the strength of a balanced, value-creating biotechnology model.
  • We also believe that our determination to be responsible citizens having a positive impact on patients, the environment and society will sustain our success in the long term.
  • Lung Biotechnology is the first public benefit corporation subsidiary of a public biotechnology or pharmaceutical company.

Arena Pharmaceuticals and United Therapeutics Announce Global License Agreement for Ralinepag

Retrieved on: 
Thursday, November 15, 2018
United Therapeutics, Business, LGBT, Gender, Martine Rothblatt

Under the terms of the agreement, Arena will grant United Therapeutics exclusive, worldwide rights to develop, manufacture and commercialize ralinepag.

Key Points: 
  • Under the terms of the agreement, Arena will grant United Therapeutics exclusive, worldwide rights to develop, manufacture and commercialize ralinepag.
  • "We believe ralinepag has the potential to transform the treatment of PAH," said Amit D. Munshi, President and Chief Executive Officer of Arena.
  • "We are thrilled to partner with United Therapeutics, based on their long-standing, deep commitment to the PAH community.
  • "We are very impressed with the clinical development plan and FDA coordination being managed by Arena," said Martine Rothblatt, Ph.D., Chairman and Chief Executive Officer of United Therapeutics.

Nilda Mesa Joins The United Therapeutics Corporation Board Of Directors

Retrieved on: 
Thursday, November 1, 2018
Business, LGBT, Gender, Martine Rothblatt, United Therapeutics

and RESEARCH TRIANGLE PARK, N.C., Nov. 1, 2018 /PRNewswire/ --United Therapeutics Corporation (NASDAQ: UTHR) announced today the appointment of Nilda Mesa to its Board of Directors as an independent director.

Key Points: 
  • and RESEARCH TRIANGLE PARK, N.C., Nov. 1, 2018 /PRNewswire/ --United Therapeutics Corporation (NASDAQ: UTHR) announced today the appointment of Nilda Mesa to its Board of Directors as an independent director.
  • In 2006, she founded Columbia's Office of Environmental Stewardship, one of the first in the United States for a university.
  • Mesa's outstanding achievements and executive management experience,"said Martine Rothblatt, Ph.D., United Therapeutics' Chairman and Chief Executive Officer.
  • United Therapeutics Corporation focuses on the strength of a balanced, value-creating biotechnology model.

United Therapeutics And XVIVO Perfusion Announce Collaboration To Reduce Organ Shortage Through Expansion Of Organ Evaluation Service

Retrieved on: 
Tuesday, June 12, 2018
Gender, LGBT, Martine Rothblatt, United Therapeutics, XVIVO Scientific Animation, Perfusion, Business

"I am excited about trying to make more life-saving use of donated lungs via XVIVO Perfusion's pioneering technology," said Martine Rothblatt, Ph.D., Chairman and Chief Executive Officer of United Therapeutics.

Key Points: 
  • "I am excited about trying to make more life-saving use of donated lungs via XVIVO Perfusion's pioneering technology," said Martine Rothblatt, Ph.D., Chairman and Chief Executive Officer of United Therapeutics.
  • "United Therapeutics' impressive history of developing and delivering innovative and effective therapies for severe lung diseases makes them the ideal partner for XVIVO Perfusion in our quest to prevent mortality due to organ shortages," said Dr. Magnus Nilsson, Chief Executive Officer of XVIVO Perfusion.
  • XPS is an integrated system that provides clinicians with the flexibility to evaluate lungs before transplantation by means of a standardized and simplified procedure.
  • In May 2018, XVIVO Perfusion submitted a premarket approval (PMA) application to the U.S. Food and Drug Administration (FDA) for the XPS with STEEN Solution.